Hsbc Holdings PLC Sells 15,412 Shares of Omnicell, Inc. $OMCL

Hsbc Holdings PLC reduced its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 48.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,417 shares of the company’s stock after selling 15,412 shares during the quarter. Hsbc Holdings PLC’s holdings in Omnicell were worth $748,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of OMCL. Cerity Partners LLC grew its position in shares of Omnicell by 4.9% during the 4th quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after buying an additional 354 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after acquiring an additional 424 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Omnicell by 0.3% in the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after acquiring an additional 448 shares in the last quarter. Diversified Trust Co. lifted its stake in Omnicell by 7.5% in the fourth quarter. Diversified Trust Co. now owns 7,965 shares of the company’s stock worth $361,000 after acquiring an additional 555 shares during the period. Finally, First Horizon Corp lifted its stake in Omnicell by 54.6% in the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock worth $72,000 after acquiring an additional 564 shares during the period. 97.70% of the stock is owned by institutional investors.

Insider Activity at Omnicell

In other Omnicell news, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares in the company, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by company insiders.

Omnicell Stock Performance

OMCL stock opened at $45.94 on Wednesday. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 104.41, a PEG ratio of 1.21 and a beta of 0.96. The firm has a 50-day simple moving average of $42.40 and a two-hundred day simple moving average of $41.50. Omnicell, Inc. has a one year low of $26.84 and a one year high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same period last year, the business earned $0.26 EPS. The company’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, equities analysts forecast that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. KeyCorp raised their target price on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Zacks Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Craig Hallum reissued a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.